| Document |
Document Title |
|
WO/2024/063545A1 |
The present invention relates to a composition comprising a Lactobacillus plantarum strain for improving intestinal metabolite composition. The Lactobacillus plantarum strain according to one embodiment can reduce intestinal polyamines (...
|
|
WO/2024/064391A2 |
This present disclosure relates to a method of generating an immune response using an antigenic material in combination with compounds that activate protein kinase C (PKC) as an adjuvant, particularly in vaccination against pathogenic ag...
|
|
WO/2024/064947A1 |
Disclosed herein are compositions and methods for inhibiting pigmentation of hair or skin. The compositions of the disclosure comprise an effective amount of a compound used for inhibition of pigmentation.
|
|
WO/2024/064630A1 |
The present invention is directed to a method of treating a patient diagnosed with or suffering from heart failure with preserved ejection fraction (HFpEF) by administering an effective amount of a peripherally-acting antihypertensive ag...
|
|
WO/2024/060966A1 |
The present invention relates to a pan-KRAS inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating cancers, tumors, inflam...
|
|
WO/2024/062043A1 |
The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein R1, R2, R3, and R4 have the same meaning as that defined in the claims and the description. The present invention also relates to the use ...
|
|
WO/2024/063670A1 |
The present invention relates to novel compounds of formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, which exhibit the properties of a CDK7 inhibitor, as well as to a pharmaceutical composition containin...
|
|
WO/2024/062250A1 |
The present invention relates to compounds of Formula (I) that may act as inhibitors of checkpoint kinase 1 (Chk1). The invention also relates to pharmaceutical compositions comprising those compounds, and to their use in the treatment o...
|
|
WO/2024/062089A1 |
A compound with the Formula (I): A-B-C wherein A is of the following formula (II): where X1 is C-RA1; B is of formula (B-1) or (B-2) and C is selected from the group consisting of optionally substituted C6-10 carboaryl, C5-6 heteroaryl a...
|
|
WO/2024/061362A1 |
The present invention provides a compound for preventing and treating vasodilator diseases, a preparation method therefor, and use thereof. Specifically, the present invention provides a compound of formula I and use thereof in treating ...
|
|
WO/2024/064917A1 |
The present embodiments relate to an aphaeretic biopsy system. The aphaeretic biopsy system can implement a dialysis-like process to obtain a bloodstream by a draw line, separate released tumor cells (RTCs) from the bloodstream, capture ...
|
|
WO/2024/062500A1 |
An anti-infective agent for use in treatment of candidiasis is disclosed. A method of treating candidiasis is also disclosed. Said method comprises step of: administering an anti-infective agent, at a dosage that ranges between about 90 ...
|
|
WO/2024/063712A1 |
The present invention relates to the preparation of pharmaceutical compositions comprising azelastine hydrochloride and fluticasone propionate for the symptomatic treatment of seasonal allergic rhinitis in patients 6 years of age and old...
|
|
WO/2024/064209A1 |
Described herein are treatments of infections and diseases caused by pathogenic bacteria, including the treatment of infections and diseases caused by Mycobacteriaceae.
|
|
WO/2024/063570A1 |
The present invention relates to an antisense oligonucleotide (ASO) that targets myotonic dystrophy protein kinase (DMPK) and use thereof. More specifically, the present invention relates to: an antisense oligonucleotide fused with an ad...
|
|
WO/2024/061665A1 |
The invention relates to isoxazoline compounds of formula I wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for p...
|
|
WO/2024/064178A1 |
This disclosure relates to, inter alia, certain compounds, compositions, and pharmaceutical compositions thereof, that modulate the activity of the transporter protein vesicular monoamine transporter-2 (VMAT2) and are directed to methods...
|
|
WO/2024/063648A1 |
The present invention is directed to a scaffold and a compound for targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts (CAFs). The scaffold comprises a (4-quinoinolyl)glycinyl-2-cyanopyrrolidine scaffold that i...
|
|
WO/2024/061298A1 |
The present invention relates to a heterocyclo-substituted methanone derivative and the use thereof. In particular, the present invention provides a solid form of (S)-(3-amino-5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperid
in]-1'-yl)pyr...
|
|
WO/2024/062675A1 |
Provided are: a stratum corneum formation promoter that promotes stratum corneum formation through the activation of olfactory receptors; a skin roughness inhibitor; a moisturizing agent; a skin barrier function improving agent; a melani...
|
|
WO/2024/061118A1 |
The present invention provides a macrocyclic nitrogen-containing crown ether compound represented by formula (I) and use thereof as a protein kinase inhibitor.
|
|
WO/2024/064080A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2024/064683A2 |
Compositions comprising an RNA molecule comprising a guide sequence portion having 17- 50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-34194 and methods and uses thereof.
|
|
WO/2024/063246A1 |
An electronic device, according to one embodiment, comprises: a cartridge accommodation unit for accommodating a cartridge having an emulsion therein; a crushing circuit comprising a crushing element capable of crushing at least a portio...
|
|
WO/2024/063633A1 |
This invention belongs to the technical field of functional foods and preserving or maintaining the viability of microorganisms. The subject matter of the invention relates to a method for obtaining a probiotic enriched with a granular p...
|
|
WO/2024/060649A1 |
The present invention provides an siRNA or a pharmaceutically acceptable salt for inhibiting the expression of TMPRSS6 in a human cell, and a proper modification is made to the siRNA to improve the silencing capability against a target a...
|
|
WO/2024/064606A2 |
Compositions comprising an RNA molecule comprising a guide sequence portion having 17- 50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-4886 and methods and uses thereof.
|
|
WO/2024/061673A1 |
The present invention relates to an injectable hydrogel for drug delivery, preferably ocular drug delivery, wherein the hydrogel is comprised of a polymer comprised of an AB and/or ABA block co-polymer and at least one drug compound co-p...
|
|
WO/2024/061333A1 |
Provided are a compound of formula I having KRas inhibitory activity, a pharmaceutical composition comprising the compound, a preparation method therefor, and use thereof. The compound has remarkable selectivity, inhibitory activity, and...
|
|
WO/2024/062395A1 |
The present disclosure relates to methods of treating metabolic conditions by administrating 5-methoxy-2-aminoindan, or a salt thereof, to a subject in need thereof in a therapeutically effective amount. The disclosure also relates to me...
|
|
WO/2024/059904A1 |
Provided herein are compositions and methods for the treatment of fibrosis using miR-25 mimics. More particularly, disclosed herein are novel miR mimetics, and methods for attenuating fibrosis progression in a subject, particularly liver...
|
|
WO/2024/064623A2 |
Compositions comprising an RNA molecule comprising a guide sequence portion having 17- 50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-6833 and methods and uses thereof.
|
|
WO/2024/064288A1 |
The present disclosure relates to methods and compositions useful for treating cancer in a subject in need thereof. Said methods and compositions comprising inhibitors of toll-like receptor 4 (TLR4) signaling.
|
|
WO/2024/061554A1 |
A PARP7 inhibitor compound comprises formula (I), X1 is selected from C, and N. R1, R2, and R3, are each independently H or an organic group. R9 is H or an organic group, or is absent when X1 is N. L is (II). Each R4 is independently sel...
|
|
WO/2024/062344A1 |
The present disclosure encompasses Mesdopetam salts, solid state forms of Mesdopetam and salts thereof, in embodiments processes for preparation thereof and pharmaceutical compositions thereof.
|
|
WO/2024/064721A2 |
The present disclosure is concerned with methods of treating disorders associated with overexpression of an eyes absent (EYA) protein such as, for example, vascular disease, a fibrosis-related disorder, hearing loss, and a metabolic dise...
|
|
WO/2024/060359A1 |
The present invention relates to use of a glycerophospholipid compound in the prevention and treatment of hyperlipidemia, atherosclerosis, a non-alcoholic fatty liver disease, and obesity. Specifically, the present invention relates to u...
|
|
WO/2024/063143A1 |
The present invention relates to a compound represented by formula (I) or (II) or a pharmaceutically acceptable salt thereof. Formula (I): [wherein: A1 is C(R1), etc.; R1 is a hydrogen atom, etc.; R8 is a hydrogen atom, etc.; B1 is CH,...
|
|
WO/2023/156996A9 |
The invention provides novel inhibitors of MetAp2 enzymatic activity and uses thereof.
|
|
WO/2024/061960A1 |
The invention relates to 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino
)propyl]-8- azabicyclo[3.2.1]oct-3-yl}amide (velusetrag) or a pharmaceutically acceptable salt...
|
|
WO/2024/063770A1 |
The present disclosure provides a liquid formulation comprising belumosudil, a processes for preparing a liquid formulation of belumosudil, and liquid pharmaceutical compositions comprising belumosudil which may be used in the treatment ...
|
|
WO/2024/062471A1 |
Botanical extracts are provided, which comprise ethanol extracts of Nannochloropsis algae having between 10wt% and 50wt% polar lipids and between 45wt% and 60wt% fatty acids, wherein the fatty acids comprise more than 10wt% of eicosapent...
|
|
WO/2024/061357A1 |
The present invention relates to the field of pharmaceutical compounds, and relates to a harringtonine derivative, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. The harringtonine derivative and t...
|
|
WO/2024/061172A1 |
Disclosed is a prolyl hydroxylase inhibitor, which belongs to the technical field of medicines. The present invention provides a pyridino-triazole compound having a structure represented by the formula below. The pyridino-triazole compou...
|
|
WO/2024/060864A1 |
The present invention relates to use of a competitive SNAT2 inhibitor or gene expression inhibition in preparing a medicament for preventing and/or treating hypertension. The competitive SNAT2 inhibitor is α-aminoisobutyric acid (MeAIB)...
|
|
WO/2024/062236A1 |
The present invention relates to a combination comprising at least four antimicrobial agents selected from rifampicin, levofloxacin, polymyxin E, polymyxin B, doxycycline, ceftazidime, and pharmaceutically acceptable derivatives thereof....
|
|
WO/2023/221945A9 |
Methods for alleviating a condition caused by abnormal subcutaneous deposit of adipose tissue or fat in a subject in need thereof an effective amount of a composition comprising a first active agent, which comprises (i) a resveratrol com...
|
|
WO/2024/063578A1 |
The present invention relates to a novel tetraheterocycle compound and, more specifically, to a novel tetraheterocycle compound useful as a KRAS protein inhibitor, an isomer, and a pharmaceutical composition for cancer treatment comprisi...
|
|
WO/2024/064748A2 |
The present disclosure provides compositions and methods related to engineered extracellular vesicles (EVs). In particular, the present disclosure provides a novel exosome-specific delivery scaffold for administering therapeutic agents t...
|
|
WO/2024/064823A2 |
Provided herein, inter alia, are compositions comprising a staurosporine analog and methods for their use in cancer treatment.
|
